BRIP1 and rheumatoid arthritis: In this study, we identified auranofin, an FDA-approved anti–rheumatoid arthritis agent, as a TOPBP1 inhibitor with high potency in disrupting the interaction of TOPBP1 with PHF8 and FANCJ by docking to the hydrophobic pocket of BRCT 7–8.